The Latest Research Progress of Non-alcoholic Fatty Liver Disease-related Hepatocellular Carcinoma
DOI:
https://doi.org/10.53469/jcmp.2024.06(07).11Keywords:
Non-alcoholic fatty liver disease, Hepatocellular carcinoma, Means of treatment, Research progressAbstract
In modern society, with the improvement of people's living standards and the change of diet structure, non-alcoholic fatty liver disease (NAFLD) has become one of the most common chronic liver diseases worldwide. This disease seriously affects the quality of life of patients, and may also lead to serious complications such as cirrhosis and liver cancer, which brings heavy life burden to patients and their families. The incidence of hepatocellular carcinoma (HCC) in patients with NAFLD is significantly higher than that in patients without NAFLD. The risk of HCC in patients with NAFLD is closely related to the severity of fatty liver and the degree of liver fibrosis. The occurrence of HCC in patients with NAFLD is also related to metabolic diseases such as insulin resistance, obesity, and type 2 diabetes. This article focuses on the epidemiology, pathogenesis, early diagnosis and treatment of HCC.
References
Fan Jiangao, Zeng Jing. Prevalence and harm of non-alcoholic fatty liver disease [J]. Chin J Gastroenterol, 2020, 40(9):577-580.
Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030[J]. J Hepatol, 2018, 69(4): 896-904.
Bengtsson B, Stal P, Wahlin S, et al. Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis[J]. Liver Int, 2019, 39(6):1098-1108.
Loomba R, Friedman S L, Shulman G I. Mechanisms and disease consequences of nonalcoholic fatty liver disease[J]. Cell, 2021, 184(10): 2537-2564.
Arroyave-Ospina J C, Wu Z, Geng Y, et al. Role of oxidative stress in the pathogenesis of non-alcoholic fatty liver disease: Implications for prevention and therapy[J]. Antioxidants, 2021, 10(2): 174.
Chen Z, Tian R, She Z, et al. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease[J]. Free Radical Biology and Medicine, 2020, 152: 116-141.
Olszak T, An D, Zeissig S, et al. Microbial exposure during early life has persistent effects on natural killer T cell function[J]. Science, 2012, 336(6080): 489-493.
Albillos A, De Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy[J]. Journal of hepatology, 2020, 72(3): 558-577.
Wang B, Tontonoz P. Phospholipid remodeling in physiology and disease[J]. Annual review of physiology, 2019, 81: 165-188.
Department of Medical Administration, National Health Commission of the People's Republic of China. Guideline for diagnosis and treatment of primary liver cancer (2024 edition) [J]. Chin J General Surgery, 2024, 33(4):475-530.
Mikolasevic I, Filipec-Kanizaj T, Mijic M, et al. Nonalcoholic fatty liver disease and liver transplantation-where do we stand? [J]. World journal of gastroenterology, 2018, 24(14): 1491.
Straś W, Małkowski P, Tronina O. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis–epidemiology, risk factors, clinical implications and treatment[J]. Clinical and experimental hepatology, 2020, 6(3): 170-175.
Marrero J A, Kulik L M, Sirlin C B, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 68(2): 723-750.
Campani C, Bensi C, Milani S, et al. Resection of NAFLD-associated HCC: patient selection and reported outcomes[J]. Journal of hepatocellular carcinoma, 2020: 107-116.
Viganò L, Conci S, Cescon M, et al. Liver resection for hepatocellular carcinoma in patients with metabolic syndrome: a multicenter matched analysis with HCV-related HCC[J]. Journal of hepatology, 2015, 63(1): 93-101.
Liu L, **e S, Teng Y X, et al. Outcomes of liver resection for metabolic dysfunction-associated fatty liver disease or chronic hepatitis B-related HCC[J]. Frontiers in oncology, 2022, 11: 783339.
Castelló B, Aguilera V, Blázquez M T, et al. Post-transplantation outcome in non-alcoholic steatohepatitis cirrhosis: Comparison with alcoholic cirrhosis[J]. Annals of Hepatology, 2019, 18(6): 855-861.
Wong C R, Njei B, Nguyen M H, et al. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non‐alcoholic fatty liver disease[J]. Alimentary pharmacology & therapeutics, 2017, 46(11-12): 1061-1069.
Young S, Sanghvi T, Rubin N, et al. Transarterial chemoembolization of hepatocellular carcinoma: propensity score matching study comparing survival and complications in patients with nonalcoholic steatohepatitis versus other causes cirrhosis[J]. CardioVascular and Interventional Radiology, 2020, 43: 65-75.
Howell J, Samani A, Mannan B, et al. Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study[J]. Therapeutic advances in gastroenterology, 2022, 15: 17562848221100106.
Hiraoka A, Kumada T, Tada T, et al. Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study[J]. Scientific reports, 2021, 11(1): 16663.
Pfister D, Núñez N G, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC[J]. Nature, 2021, 592(7854): 450-456.
Chen K, Wei W, Liu L, et al. Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice[J]. Cancer Immunology, Immunotherapy, 2021: 1-12.
Baumeister S E, Schlesinger S, Aleksandrova K, et al. Association between physical activity and risk of hepatobiliary cancers: a multinational cohort study[J]. Journal of hepatology, 2019, 70(5): 885-892.
Kim G, Jang S Y, Nam C M, et al. Statin use and the risk of hepatocellular carcinoma in patients at high risk: a nationwide nested case-control study[J]. Journal of hepatology, 2018, 68(3): 476-484.
Kwak M, Mehaffey J H, Hawkins R B, et al. Bariatric surgery is associated with reduction in non-alcoholic steatohepatitis and hepatocellular carcinoma: a propensity matched analysis[J]. The American Journal of Surgery, 2020, 219(3): 504-507.
Kennedy O J, Roderick P, Buchanan R, et al. Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: a systematic review and dose–response meta-analysis[J]. BMJ open, 2017, 7(5): e013739.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Qihua Feng, Linxun Liu, Mengzhao Xu, Fei Ke, Runwu Cao
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
